Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.

Nature biotechnology - 1 May 1998

Chase M, Chung R Y, Chiocca E A

Abstract excerpt

Herpes simplex viruses type 1 (HSV-1) with an inactivated viral ribonucleotide reductase (Hsrr, ICP6) were designed to target tumor cells with upregulated mammalian ribonucleotide reductase (mRR), an enzyme whose expression is regulated by the p16/pRB tumor suppressor pathway. A recombinant HSV-1 was generated by knock-out of Hsrr and insertion of the rat CYP2B1 transgene responsible for the bioactivation of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA, Viral
Share to Gene Expression Regulation, Enzymologic
Share to Mice

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Mutation

Share to Recombinant Proteins

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 9592392
DOI: 10.1038/nbt0598-444

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy.PMID 9592392Read ↗

Oncolytic herpes simplex virus vectors for cancer virotherapy.Semantic proximity Read ↗

Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.Semantic proximity Read ↗

Treatment of malignant gliomas using ganciclovir-hypersensitive, ribonucleotide reductase-deficient herpes simplex viral mutant.Semantic proximity Read ↗

Preclinical Toxicology of rQNestin34.5v.2: An Oncolytic Herpes Virus with Transcriptional Regulation of the ICP34.5 Neurovirulence GeneSemantic proximity Read ↗

Enhanced cytotoxicity of reovirus and radiotherapy in melanoma cells is mediated through increased viral replication and mitochondrial apoptotic signalling.Semantic proximity Read ↗

Effects of tumor selective replication-competent herpes viruses in combination with gemcitabine on pancreatic cancer.Semantic proximity Read ↗

Triple-mutated oncolytic herpes virus for treating both fast- and slow-growing tumors.Semantic proximity Read ↗

Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization.Semantic proximity Read ↗

Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.Semantic proximity Read ↗

Augmented therapeutic efficacy of an oncolytic herpes simplex virus type 1 mutant expressing ICP34.5 under the transcriptional control of musashi1 promoter in the treatment of malignant glioma.Semantic proximity Read ↗

Enhancement of antitumor activity of herpes simplex virus gamma(1)34.5-deficient mutant for oral squamous cell carcinoma cells by hexamethylene bisacetamide.Semantic proximity Read ↗

Antitumor activity and reporter gene transfer into rat brain neoplasms inoculated with herpes simplex virus vectors defective in thymidine kinase or ribonucleotide reductase.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.